Actively Recruiting
Randomized, Placebo-Controlled Study Evaluating Safety and Immune Response of TRB-001 in Adults with Early Idiopathic Parkinsons Disease
Led by Tridem Bioscience FlexCo · Updated on 2026-09-24
36
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating TRB-001, a biological solution given by intradermal injection, in patients aged 40 to 75 with early idiopathic Parkinsons Disease. This randomized, placebo-controlled, double-blind phase 1b study aims to assess the safety, immune response, and pharmacodynamics of TRB-001, including its effects compared to placebo in early Parkinsons patients. The study is sponsored by Tridem Bioscience FlexCo and uses a sequential design to test different doses. Participants receive one of several doses of TRB-001 or a placebo via intradermal injection. The doses include 20 g 0.1 ml, 40 g 0.2 ml, or 100 g 0.5 ml administered as low dose, high dose, or logarithmic dosing. The study evaluates treatment over six months, focusing on safety and immune response, with an extension up to 18 months to assess symptom progression. During participation, patients undergo assessments including monitoring of treatment-emergent adverse events, immunogenicity testing, and clinical evaluations of Parkinsons symptoms using standardized scales such as MDS-UPDRS II and III. Brain MRI results confirm diagnosis. The study includes follow-up visits over 18 months to evaluate motor and non-motor symptom progression, biomarker collection, and safety monitoring. Participants are expected to comply with study procedures and provide informed consent.
CONDITIONS
Brief Title
Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease
Research Team
C
CEO Tridem
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here